Cell therapies have the potential to revolutionize the biopharmaceutical world, but today’s processes, logistics, and delivery make for a challenging entry into the sector’s growth curve. As the industry evolves, we will have to answer (at least) three important questions when bringing these exciting new therapies to market:
What benefit does the therapy provide in terms of patient longevity and product efficacy?
What will the cost of the new therapy be, especially in the early stages of low volumes, and how can process manufacturing impact that cost?
How can we, as an industry, provide the therapy that requires, in some cases, the patient to be resident/connected for cell collection and re-infusion, given that the scale of operation may force the providers to have only one national manufacturing site for the therapy?